Print

Purpose

The purpose of this study is to determine if the reparative cells of blood vessels called endothelial progenitor cells(EPC) are defective in people with diabetes.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Any man or woman - Greater than 18 years of age - Diagnosis of diabetes (applies to the Diabetic Arm only) (N=15 Type 1 and N=15 Type - The subject must be willing and have the ability to cooperate with the protocol. Children will not be eligible because the investigators need to obtain 150 ml of blood and this is in excess of what can be drawn in children.

Exclusion Criteria

  • Female participants must not be pregnant at the time of the blood draw as evident through a dipstick pregnancy test. - Have retinal abnormalities other than diabetic retinopathy.

Study Design

Phase
Study Type
Observational
Observational Model
Case-Control
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Group 1 Diabetic
  • Other: 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy
    Other names:
    • NPDR - Non Proliferative Diabetic Retinopathy
    • PDR -Proliferative Diabetic Retinopathy
Group 2 Healthy Controls
  • Other: Healthy Controls 15 age matched control subjects

Recruiting Locations

University of Alabama at Birmingham
Birmingham, Alabama 35294
Contact:
Maris B Grant, MD, PhD
317-274-2628
mabgrant@iupui.edu

More Details

Status
Recruiting
Sponsor
University of Alabama at Birmingham

Study Contact

Jennifer Moorer
205 325 8674
jmoorer@uabmc.edu

Detailed Description

The purpose of this study is to determine if the reparative cells of blood vessels, called endothelial progenitor cells (EPC's) are defective in people with diabetes. Diabetic retinopathy (DR) is an eye disease related to diabetes. It can cause blurred vision and possible bleeding in the blood vessels in the back of the eye (retina). Damage to the cells of the blood vessels from DR can cause vision loss or blindness. Even with current treatments, the quality of life for people with DR is much reduced.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.